Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Opdivo Qvantig Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAnthemPolicy CC-0281

    Opdivo Qvantig (nivolumab hyaluronidase‑nvhy) — Medical Drug Clinical Criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0281 alerts

    Get alerted when Policy CC-0281 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical drug clinical criteria governing use and coverage determinations for Opdivo Qvantig (a subcutaneous formulation of nivolumab with hyaluronidase) for Anthem members; applies to clinical review and prior authorization decisions.

    Policy Summary
    PayerAnthem
    PolicyOpdivo Qvantig (nivolumab hyaluronidase‑nvhy) — Medical Drug Clinical Criteria
    Policy CodePolicy CC-0281
    Change TypeSelect review / alignment to Opdivo Qvantig criteria (no material clinical changes)
    Effective Date
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionSubmit prior authorization with diagnosis, line of therapy, ECOG 0–2, prior therapy history and relevant biomarker results (dMMR/MSI‑H, POLE/POLD1, TMB, PD‑L1) as applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~20+cancer types listed
    NCCN 1/2ANCCN support
    ECOG 0-2ECOG requirement
    MSI‑H / TMBbiomarker references
    contraindicationimmunosuppressant exclusion

    Coverage criteria and indications

    Coverage criteria and indications

    Covered when the use matches FDA-approved indications for Opdivo Qvantig or when Opdivo Qvantig is substituted for intravenous nivolumab per NCCN-supported recommendations; diagnosis-specific criteria below must also be met.

    FDA Indications: Use consistent with any FDA-approved indication for Opdivo Qvantig (e.g., RCC, melanoma, NSCLC, SCCHN, urothelial carcinoma, MSI-H/dMMR CRC, HCC, ESCC, gastric/GEJ/EA)

    See FDA indications in chunks 3-12

    Substitution for IV nivolumab: Opdivo Qvantig may be substituted for intravenous nivolumab where clinically appropriate and supported by NCCN category 1 or 2A recommendations

    Package insert notes Opdivo Qvantig is not indicated in combination with ipilimumab (chunk 3, 12)

    General clinical requirements: Prior authorization documentation must support diagnosis, line of therapy, ECOG 0-2 (or Karnofsky 60-100 where specified), prior therapy history, and biomarker status where applicable; patient is not receiving systemic immunosuppressant therapy for autoimmune/chronic conditions; individual is not under 19 years of age unless a pediatric indication is specified
    Policy Summary
    PayerAnthem
    PolicyOpdivo Qvantig (nivolumab hyaluronidase‑nvhy) — Medical Drug Clinical Criteria
    Policy CodePolicy CC-0281
    Change TypeSelect review / alignment to Opdivo Qvantig criteria (no material clinical changes)
    Effective Date
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionSubmit prior authorization with diagnosis, line of therapy, ECOG 0–2, prior therapy history and relevant biomarker results (dMMR/MSI‑H, POLE/POLD1, TMB, PD‑L1) as applicable.
    SourceLink
    On This Page
    Coverage criteria and indicationsCovered regimens and combination therapiesBiomarker requirements and thresholdsLine of therapy requirements and sequencingPrior authorization, documentation, and provider requirementsBilling and diagnosis codingDefinitions and clinical termsBackground and drug descriptionPolicy revision history

    See chunks 17, 18, 36

    Covered indications (partial list)

    Covered when ALL of the following criteria for the specified cancer indication are met (per each numbered indication below):

    Indication list (selected examples): Each numbered indication below represents an AND-linked set of requirements; examples include bone cancers, anal carcinoma, appendiceal adenocarcinoma with hypermutation, CLL/SLL with Richter transformation, colorectal cancer (MSI-H/dMMR), uterine neoplasms, esophageal/EGJ cancers, gastric cancer, HCC, gestational trophoblastic disease, Hodgkin lymphoma, Kaposi sarcoma, mesothelioma, melanoma, Merkel cell carcinoma, NSCLC, RCC, extranodal NK/T-cell lymphomas, and soft tissue sarcoma (selected subtypes or TMB-H)

    See chunks 18-19, 22-26, 29-32, 35-37

    Renal cell carcinoma (RCC) — relapsed/recurrent/advanced

    Covered when ALL of the following are met (per NCCN categories cited):

    RCC relapsed/recurrent/advanced (Label, NCCN 1, 2A)

    • Histologic confirmation: Histological confirmation of RCC with clear-cell component when indicated

      See chunk 35

    • Prior anti-angiogenic therapy: Confirmation of disease progression after one or two prior anti-angiogenic regimens when using monotherapy

      See chunk 35

    • Use with cabozantinib: Using as first-line therapy or subsequent therapy in combination with cabozantinib tablets when specified

      See chunk 36

    • ECOG: Current ECOG performance status of 0-2

      See chunks 35-36

    • No prior anti-PD-1/PD-L1: Has not received treatment with another anti-PD-1 or anti-PD-L1 agent unless scenario allows prior IO

      See chunks 35-36

    • No systemic immunosuppression: Not receiving therapy for an autoimmune disease or chronic condition requiring systemic immunosuppressant

      See chunks 35-36

    RCC line-of-therapy alternative: If using subsequent therapy in combination with cabozantinib after prior immune-oncology therapy (e.g., pembrolizumab), document prior IO exposure and ECOG 0-2

    See chunk 36

    Non-clear cell RCC (nccRCC) and adjuvant continuation

    Covered when ALL of the following are met (NCCN 2A):

    nccRCC

    • Regimen: Using as systemic therapy as a single agent or in combination with cabozantinib

      See chunk 36

    • No prior anti-PD-1/PD-L1: Has not received another anti-PD-1 or anti-PD-L1 agent

      See chunk 36

    • No EGFR/ALK drivers: Individual has no known EGFR mutations or ALK rearrangements

      See chunk 36

    • Adjuvant continuation after surgery: Individual continues with Opdivo as a single agent for adjuvant treatment after surgery when specified

      See chunk 36

    • ECOG: Current ECOG performance status of 0-2

      See chunk 36

    • No systemic immunosuppression: Not receiving therapy for an autoimmune disease or chronic condition requiring systemic immunosuppressant

      See chunk 36

    Adjuvant continuation specifics: Adjuvant single-agent continuation after surgery permitted per NCCN 2A criteria

    See chunk 36

    Extranodal NK/T-cell lymphomas

    Covered when ALL of the following are met (NCCN 2A):

    Disease status: Individual has relapsed or refractory extranodal NK/T-cell lymphoma
    Prior chemotherapy: Using Opdivo Qvantig as monotherapy following alternate combination chemotherapy not previously used (e.g., asparaginase-based regimen)

    See chunk 37

    No prior anti-PD-1/PD-L1: Has not received treatment with another anti-PD-1 or anti-PD-L1 agent

    See chunk 37

    ECOG: Current ECOG performance status of 0-2

    See chunk 37

    No systemic immunosuppression: Not receiving therapy for an autoimmune disease or chronic condition requiring systemic immunosuppressant

    See chunk 37

    Soft tissue sarcoma — selected subtypes or TMB-high

    Covered when ALL of the following are met (NCCN 2A):

    Indication: Individual has advanced or metastatic soft tissue sarcoma or aggressive soft tissue neoplasm
    Subtype or biomarker: Either (1) tumor is one of specific histologies (myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, undifferentiated sarcomas) OR (2) tumor is unresectable/metastatic and TMB-high (≥10 mut/Mb)≥10 mut/Mb

    See chunk 37

    No prior anti-PD-1/PD-L1: Has not received another anti-PD-1 or anti-PD-L1 agent

    See chunk 37

    No systemic immunosuppression: Not receiving therapy for an autoimmune disease or chronic condition requiring systemic immunosuppressant

    See chunk 37

    Squamous cell skin cancer and SCCHN

    Covered when criteria below are met (NCCN 1 or 2A depending on indication):

    Squamous cell skin cancer: Using as a single agent for squamous cell skin cancer (NCCN 2A)

    See chunk 38

    SCCHN recurrent/metastatic: Individual has recurrent, unresectable, or metastatic squamous cell carcinoma of the head and neck and either (a) using as monotherapy after progression on/after platinum-containing chemotherapy OR (b) using in combination with cetuximab (NCCN 2A); may be used first- or subsequent-line

    See chunks 38-39

    Small bowel adenocarcinoma (SBA)

    Covered when ALL of the following are met (NCCN 2A):

    Disease extent: Advanced/metastatic or locally unresectable/medically inoperable small bowel adenocarcinoma
    Biomarker: Tumor has dMMR/MSI-H or POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB >50 mut/Mb)TMB >50 mut/Mb

    See chunk 41

    Use: Using as monotherapy

    See chunk 41

    ECOG: Current ECOG performance status of 0-2

    See chunk 41

    No prior anti-PD-1/PD-L1: Has not received treatment with another anti-PD-1 or anti-PD-L1 agent

    See chunk 41

    No systemic immunosuppression: Not receiving therapy for an autoimmune disease or chronic condition requiring systemic immunosuppressant

    See chunk 41

    Urothelial carcinoma — single agent and combination regimens

    Covered when ALL of the following are met (Label, NCCN 1, 2A):

    Single-agent locally advanced/metastatic: Using as a single agent for locally advanced, recurrent, or metastatic urothelial carcinoma with disease progression on or after platinum-containing or other chemotherapy, or progression within 12 months of neoadjuvant/adjuvant platinum therapy

    See chunk 42

    Combination cisplatin/gemcitabine: Using in combination with cisplatin and gemcitabine as first-line treatment for unresectable, recurrent, or metastatic disease; ECOG 0-2; no prior anti-PD-1/PD-L1; no systemic immunosuppression

    See chunk 42

    Vaginal and vulvar cancers (selected)

    Covered when ALL of the following are met (NCCN 2A):

    Vaginal cancer recurrent/metastatic: Using as a single agent for recurrent or metastatic vaginal cancer as second-line or subsequent therapy; tumor PD-L1 CPS ≥ 1%; ECOG 0-2; no prior anti-PD-1/PD-L1; no systemic immunosuppressionCPS ≥ 1%

    See chunk 47

    Vulvar cancer advanced/recurrent: Using as a single agent as second-line or subsequent therapy for advanced or recurrent metastatic vulvar cancer (HPV-related); no prior anti-PD-1/PD-L1; no systemic immunosuppression

    See chunk 47

    Head and neck, thyroid, anaplastic thyroid carcinoma, CNS pediatric high-grade gliomas

    Covered when criteria described below are met (NCCN 1 or 2A depending on tumor):

    Nasopharyngeal cancer: Recurrent, unresectable, oligometastatic, or metastatic nasopharyngeal cancers with no surgical or radiotherapy options and using nivolumab in combination with cisplatin and gemcitabine; no prior anti-PD-1/PD-L1

    See chunk 43

    Anaplastic thyroid carcinoma: Metastatic anaplastic thyroid carcinoma using as single agent; ECOG 0-2; no prior anti-PD-1/PD-L1; no systemic immunosuppression

    See chunk 43

    Pediatric diffuse high-grade gliomas: Use as adjuvant therapy or for recurrent/progressive hypermutant tumors with specified exceptions; no prior anti-PD-1/PD-L1; no systemic immunosuppression

    See chunks 43-44

    Per the product labeling, Opdivo Qvantig is not indicated in combination with ipilimumab. The package insert explicitly states that the subcutaneous nivolumab/hyaluronidase formulation should not be used together with ipilimumab, and coverage reviews will reflect this contraindication.

    Many of the diagnosis-specific coverage criteria require that the patient has not received prior treatment with another anti‑PD‑1 or anti‑PD‑L1 agent. In addition, the policy repeatedly excludes patients who are actively receiving therapy for an autoimmune disease or other chronic condition that requires systemic immunosuppression; ongoing systemic immunosuppressant therapy is a contraindication to coverage in those scenarios.

    Opdivo Qvantig is not approved for use in combination with intravenous ipilimumab (Yervoy). The policy notes this disallowed combination as a specific non‑covered use and references the package insert guidance that the subcutaneous formulation is not indicated with ipilimumab.

    Use of Opdivo Qvantig in individuals under 19 years of age is a specific review trigger in the clinical criteria and may result in non‑coverage when the age criterion is not met. Additionally, requests that do not align with the listed diagnosis‑specific requirements (for example, prior therapy history, biomarker status, or ECOG performance status) will prompt additional review and may be denied.

    Requests for Opdivo Qvantig that do not meet the stated, diagnosis‑specific coverage criteria — including required prior therapies, biomarker thresholds, or absence of contraindicating systemic immunosuppression — may be considered not medically necessary and denied under the policy.

    Covered regimens and combination therapies

    RegimenIndication / NotesCoverage status
    Opdivo Qvantig (nivolumab hyaluronidase-nvhy) administered with platinum-doublet chemotherapy
    Neoadjuvant treatment for resectable NSCLC (tumors ≥4 cm or node positive); may continue as adjuvant monotherapy after surgery where specified; substitution for IV nivolumab allowed per NCCN; ECOG 0-2 and other criteria apply
    Opdivo Qvantig in combination with other FDA- or NCCN-specified chemotherapy or targeted agents (see regimen-specific rows)
    Example combinationContext / tumor typeCoverage status
    Nivolumab (Opdivo Qvantig) + sunitinib
    Dedifferentiated chondrosarcoma — per NCCN 2A and clinical trial NCT03277924: may be used as monotherapy or combined with sunitinib; no prior anti-PD‑1/PD‑L1; not receiving systemic immunosuppressants
    Nivolumab (Opdivo Qvantig) + platinum-containing chemotherapy ± capecitabine or fluorouracil
    Esophageal / esophagogastric junction cancers — induction systemic therapy to relieve dysphagia and for patients planned for esophagectomy; first-line or monotherapy pathways described; ECOG 0-2 and other criteria apply
    Nivolumab (Opdivo Qvantig) + fluoropyrimidine + platinum
    Advanced/metastatic gastric or esophagogastric junction cancers (HER2 negative) — first-line combination per label/NCCN; ECOG 0-2; no prior checkpoint inhibitor; not receiving systemic immunosuppression
    Nivolumab (Opdivo Qvantig) + cabozantinib (tablets)
    Renal cell carcinoma (relapsed/recurrent/advanced) — first-line or subsequent therapy in combination with cabozantinib; ECOG 0-2; no prior anti-PD‑1/PD‑L1; not receiving systemic immunosuppression
    Tumor typeSingle-agent nivolumab use (notes)Coverage status
    Merkel cell carcinoma (MCC)
    Metastatic or recurrent locoregional MCC not amenable to definitive surgery or radiation; single-agent nivolumab per NCCN 2A; ECOG 0-2; no prior anti-PD‑1/PD‑L1 or progression on such therapy conditions apply
    Kaposi sarcoma
    Relapsed/refractory advanced classic Kaposi sarcoma as single-agent subsequent systemic therapy; excludes multicentric Castleman disease/KICS; not receiving systemic immunosuppression
    Malignant pleural or peritoneal mesothelioma
    Single-agent subsequent therapy for relapsed/refractory mesothelioma (NCCN 2A); ECOG 0-2; no prior anti-PD‑1/PD‑L1; not receiving systemic immunosuppression
    Melanoma (selected indications)
    Unresectable or metastatic melanoma — single-agent use per label/NCCN (NCCN 1/2A) with ECOG 0-2 and no prior anti‑PD‑1/PD‑L1; additional neoadjuvant/adjuvant criteria apply where specified
    RegimenSpecific criteria (summary)Coverage status
    Opdivo Qvantig (nivolumab) + cabozantinib (tablets)
    Relapsed, recurrent, or advanced renal cell carcinoma (Label, NCCN 1/2A): may be used as first-line or subsequent therapy in combination with cabozantinib; patient must have ECOG 0-2, no prior anti‑PD‑1/PD‑L1, and not be receiving systemic immunosuppression
    Non-clear cell RCC
    Non-clear cell RCC (including HLRCC) may be treated with single agent Opdivo Qvantig or in combination with cabozantinib per NCCN 2A; no prior anti‑PD‑1/PD‑L1; no EGFR/ALK drivers; ECOG 0-2; adjuvant continuation after surgery permitted per criteria
    RegimenIndication / NotesCoverage status
    Opdivo Qvantig (nivolumab) + cisplatin + gemcitabine
    First-line treatment for unresectable, recurrent, or metastatic urothelial carcinoma in combination with cisplatin and gemcitabine; ECOG 0-2; no prior anti‑PD‑1/PD‑L1; not receiving systemic immunosuppression
    Opdivo Qvantig as single agent
    Also covered as single agent for locally advanced/recurrent/metastatic UC after progression on platinum-containing chemotherapy or within 12 months of neoadjuvant/adjuvant platinum therapy, per label/NCCN
    RegimenSCCHN use / NotesCoverage status
    Opdivo Qvantig (nivolumab) monotherapy
    Recurrent, unresectable, or metastatic squamous cell carcinoma of the head and neck (SCCHN): single-agent use for disease progression on or after platinum-containing chemotherapy; ECOG 0-2; no prior anti‑PD‑1/PD‑L1; not receiving systemic immunosuppression
    Opdivo Qvantig + cetuximab
    Combination with cetuximab (NCCN 2A) is an alternative for first- or subsequent-line therapy per NCCN guidance
    CombinationPolicy noteCoverage status
    Opdivo Qvantig + intravenous ipilimumab (Yervoy)
    Opdivo Qvantig is not approved for use in combination with IV ipilimumab; such combination is listed as not approved and may lead to denial

    Biomarker requirements and thresholds

    inv-46: MSI-H / dMMR biomarker (key item) - required facts
    MSI-H / dMMRDeficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status required for listed indications such as metastatic colorectal cancer, appendiceal adenocarcinoma, uterine neoplasms, and small bowel adenocarcinoma
    Use scenariosIndicated as a biomarker to authorize single-agent nivolumab in metastatic or recurrent disease per tumor-specific criteria (e.g., CRC after progression on fluoropyrimidine/oxaliplatin/irinotecan)
    Documentation expectationPrior authorization requires reported dMMR/MSI-H test result in the clinical record when cited in indication-specific criteria
    inv-47: POLE / POLD1 (ultra-hypermutated) or TMB — example cited
    POLE / POLD1 (ultra-hypermutated) or TMB examplePOLE or POLD1 mutation with ultra-hypermutated phenotype (example threshold: TMB >50 mut/Mb) may qualify tumors (e.g., appendiceal, colorectal) for nivolumab
    Indication linkageListed as an alternative molecular eligibility pathway alongside dMMR/MSI-H for colorectal and appendiceal cancers
    Prior therapy contextFor metastatic CRC with POLE/POLD1 ultra-hypermutated phenotype, prior progression on fluoropyrimidine, oxaliplatin, and irinotecan is specified in many scenarios
    inv-48: dMMR / MSI-H references (supporting diagnostic biomarker requirement)
    dMMR / MSI-H requirementDeficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) is specified as a required diagnostic biomarker for multiple indications including colorectal and appendiceal cancers
    Associated coveragePresence of dMMR/MSI-H permits single-agent nivolumab per the tumor-specific criteria in the policy
    Testing noteBiomarker test results should be included in prior authorization documentation when dMMR/MSI-H is a stated eligibility criterion
    inv-49: POLE / POLD1 mutation — ultra-hypermutated e.g., TMB >50 mut/Mb
    POLE / POLD1 mutation rolePOLE or POLD1 mutations with an ultra-hypermutated phenotype are listed as eligibility biomarkers for certain tumors (e.g., appendiceal and colorectal cancer)
    Ultra-hypermutated examplePolicy gives example of ultra-hypermutated phenotype as TMB >50 mut/Mb when linked to POLE/POLD1 mutations
    Coverage implicationWhen present, POLE/POLD1 ultra-hypermutated tumors may be treated with nivolumab per the indication-specific criteria
    inv-50: PD-L1 (CPS or tumor proportion) — thresholds for specific indications
    PD-L1 (CPS or tumor proportion) thresholdsPD-L1 expression thresholds are used in specific indications: CPS ≥1 for cervical/vaginal local/regional recurrence or stage IVB; PD-L1 ≥1% (tumor proportion) for metastatic NSCLC with brain metastases
    Indication-specific usePD-L1 result must be provided when required for the covered indication (e.g., vaginal cancer requires CPS ≥1)
    Authorization requirementPD-L1 positive status should be documented in prior authorization when cited as an eligibility criterion
    inv-51: TMB thresholds — ≥10 mut/Mb (TMB-H) or >50 mut/Mb (ultra-hypermutated)
    TMB ≥10 mut/Mb (TMB-H)Tumor mutational burden ≥10 mutations per megabase is used to define TMB-high for eligibility in multiple tumor types (e.g., soft tissue sarcoma, uterine neoplasms)
    Ultra-hypermutated exampleAn ultra-hypermutated phenotype (example threshold >50 mut/Mb) is referenced for POLE/POLD1-associated tumors
    DocumentationReport TMB numeric result in clinical documentation when TMB is cited as an eligibility criterion
    inv-53: dMMR/MSI-H and POLE/POLD1 notes — POLE/POLD1 may require ultra-hypermutated phenotype
    POLE/POLD1 and ultra-hypermutated phenotypePOLE or POLD1 mutations may require demonstration of an ultra-hypermutated phenotype (example: TMB >50 mut/Mb) to meet indicated criteria
    Tumor types referencedThis requirement is applied in appendiceal, colorectal, and small bowel adenocarcinoma coverage blocks where POLE/POLD1 is cited
    Prior auth implicationWhen POLE/POLD1 are cited, prior authorization should include mutation testing and TMB result as applicable
    inv-54: TMB — ≥ 10 mut/Mb (used in sarcoma criterion)
    TMB ≥10 mut/Mb for sarcomaSoft tissue sarcoma eligibility includes unresectable or metastatic TMB-high tumors defined as TMB ≥10 mut/Mb regardless of subtype
    Subtype alternativeCoverage also applies for select histologic sarcoma subtypes (myxofibrosarcoma, UPS, dedifferentiated liposarcoma, cutaneous angiosarcoma) as an alternative pathway
    DocumentationTMB numeric result must be included in prior authorization when used to establish sarcoma eligibility
    inv-55: PD-L1 (CPS) — CPS ≥ 1% for certain vaginal cancer indications
    PD-L1 CPS ≥1% for vaginal cancerRecurrent or metastatic vaginal cancer requires PD-L1 expression CPS ≥1% for nivolumab eligibility
    Line of therapyVaginal cancer use is specified as second-line or subsequent single-agent therapy when CPS ≥1%
    DocumentationPD-L1 CPS result should be provided in prior authorization when cited for vaginal cancer coverage
    inv-52: Actionable molecular markers list (recommended prior to therapy)
    Core actionable molecular markers listActionable markers to test prior to therapy: EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET, RET, ERBB2 (HER2), NRG1
    Testing recommendationNCCN recommends testing these markers prior to initiating therapy; if tissue insufficient, repeat biopsy or plasma testing recommended
    PurposeTesting guides selection of appropriate therapy and may affect nivolumab eligibility when driver oncogenes are present or unknown

    Line of therapy requirements and sequencing

    Line-of-therapy requirements (overview)

    Some indications include explicit line-of-therapy requirements; documentation must support prior therapies and sequence:

    Line-specific FDA indications: First-line, adjuvant, neoadjuvant, and subsequent-line uses are listed per tumor type (e.g., first-line RCC combinations; neoadjuvant/adjuvant NSCLC; adjuvant urothelial carcinoma; subsequent-line MSI-H CRC)

    See chunks 6, 8, 9, 35-36

    Line-of-therapy conditions (examples)

    Line-of-therapy conditions across multiple indications (examples):

    Second-line or subsequent therapy examples: Anal carcinoma, uterine neoplasms (single agent second-line), mesothelioma (subsequent therapy), appendiceal/metastatic colorectal in some scenarios require prior lines of therapy

    See chunks 18, 23, 24, 30

    First-line examples: ESCC in combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line; RCC in combination with cabozantinib as first-line in some settings; gastric/EGJ first-line combinations per criteria

    See chunks 11, 36, 29

    Neoadjuvant / adjuvant examples: Colorectal neoadjuvant for resectable T4b; resectable NSCLC neoadjuvant with platinum-doublet; gastric postoperative single-agent for completely resected MSI-H/dMMR after preoperative nivolumab+ipilimumab; resected melanoma adjuvant therapy

    See chunks 6, 12, 31

    Line-of-therapy rules (selected indications)

    Specific indications' line-of-therapy rules (examples):

    RCC/Urothelial/Vaginal examples: RCC: combination with cabozantinib may be first-line or subsequent (chunk 36). Urothelial carcinoma: combination with cisplatin/gemcitabine is first-line (chunk 42). Vaginal cancer: single-agent use is second-line or subsequent and requires PD-L1 CPS ≥1% (chunk 47)

    See chunks 36, 42, 47

    Prior authorization, documentation, and provider requirements

    Prior Authorization

    Clinical prior authorization applies — age, diagnosis, prior therapies, biomarkers

    Prior authorization review will apply clinical criteria including patient age, diagnosis-specific criteria, prior therapies (including prior anti-PD-1/PD-L1 exposure), biomarker status where specified (dMMR/MSI-H, POLE/POLD1, TMB, PD-L1), ECOG performance status, and absence of contraindicating systemic immunosuppression.

    • Applies to medical benefit prior authorization and clinical review processes.
    • Review includes age (use in individuals under 19 years is a specific review trigger).
    • Biomarker and prior therapy information must be provided when required for the indication.
    Prior Authorization

    Prior authorization required — include diagnosis, line of therapy, biomarkers

    Prior authorization is required and requests must include clinical information showing the diagnosis, intended line of therapy, prior treatments, ECOG performance status (when specified), and biomarker status when applicable (dMMR/MSI-H, POLE/POLD1, TMB, PD-L1).

    • Policy specifies documentation of diagnosis and line of therapy for each tumor-specific criterion.
    • Provide prior therapy history (e.g., prior platinum chemotherapy for NSCLC, prior anti-angiogenic regimens for RCC) when indicated.
    • Include PD-L1, dMMR/MSI-H, POLE/POLD1 or TMB results when these biomarkers are required for coverage.
    Prior Authorization

    PA requires indication-specific documentation (diagnosis, ECOG 0–2, prior therapy, biomarkers)

    Prior authorization approvals require indication-specific documentation: confirm diagnosis, current ECOG performance status 0–2 (or Karnofsky 60–100 where specified), prior therapy history per the indication, and biomarker results when applicable.

    • For many indications the policy requires ECOG 0–2 as part of the approval criteria.
    • Document prior exposure or absence of prior anti‑PD‑1/PD‑L1 agents as noted per indication.
    • Submit laboratory/pathology reports showing dMMR/MSI‑H, POLE/POLD1, TMB, or PD‑L1 when those are part of the indication.
    Step Therapy

    Prior systemic therapy requirements for NSCLC and urothelial cancer

    For NSCLC and urothelial carcinoma, prior systemic therapy or documented progression on specified systemic regimens is required per the indication (e.g., progression on or after platinum-based chemotherapy for metastatic NSCLC; progression during/after platinum-containing chemotherapy or within 12 months of neoadjuvant/adjuvant platinum for urothelial carcinoma).

    • NSCLC metastatic setting: progression on or after platinum-based chemotherapy; EGFR/ALK alterations must have progressed on approved targeted therapy before PD‑1 use.
    • Urothelial carcinoma: progression during/after platinum-containing chemotherapy or progression within 12 months of neoadjuvant/adjuvant platinum chemo.
    • Neoadjuvant/adjuvant NSCLC uses are specified separately (neoadjuvant with platinum-doublet for resectable tumors ≥4 cm or node positive).
    Step Therapy

    Required prior therapies (colorectal, RCC examples)

    Several indications explicitly require prior specific therapies before nivolumab coverage — e.g., metastatic colorectal cancer after progression on fluoropyrimidine, oxaliplatin, and irinotecan; RCC after one or two prior anti‑angiogenic regimens.

    • Colorectal (MSI‑H/dMMR): progression following fluoropyrimidine, oxaliplatin, and irinotecan for metastatic disease.
    • RCC: confirmation of disease progression after one or two prior anti‑angiogenic regimens (examples listed: axitinib, bevacizumab, pazopanib, sorafenib, sunitinib).
    Step Therapy

    Step therapy added — see revision history

    A step therapy requirement was added to the policy; see the policy revision history for details of the new step therapy requirement and effective dates.

    • Document History entry notes: 'A new step therapy was added for use of Opdivo Qvantig.'
    • Coding and policy updates are listed in the Document History (05/16/2025 entry).
    Documentation Required

    Indication and guideline documentation — FDA label or NCCN support required

    Documentation submitted with the PA must support the indicated FDA‑labeled use or NCCN substitution where applicable; when substituting for IV nivolumab reference the relevant NCCN 1 or 2A recommendations.

    • Provide clinical notes and citations that align the requested use with an FDA indication or NCCN 1/2A recommendation for substitution.
    • Package insert states Opdivo Qvantig may be substituted for intravenous nivolumab and is not indicated in combination with ipilimumab.
    Documentation Required

    Supportive documentation — histology and prior therapy evidence

    Supportive documentation must demonstrate histologic confirmation and specific prior therapy history when required by the indication (e.g., histologic confirmation of RCC with clear‑cell component; prior anti‑angiogenic therapy for RCC; prior platinum chemotherapy for NSCLC).

    • Include pathology reports confirming histology where the indication specifies (RCC clear‑cell component).
    • Provide treatment records showing prior anti‑angiogenic or platinum‑based chemotherapy when required by the tumor‑specific criteria.
    Documentation Required

    Required clinical documentation — ECOG, prior PD‑1/PD‑L1 exposure, immunosuppression status

    Required clinical documentation includes current ECOG performance status (0–2 or Karnofsky 60–100 where specified), explicit record of prior exposure to anti‑PD‑1/PD‑L1 agents (or confirmation of no prior exposure where required), and documentation that the patient is not receiving systemic immunosuppressant therapy for autoimmune or chronic conditions.

    • ECOG 0–2 is repeatedly required across indications; record the score in clinical notes.
    • Document prior anti‑PD‑1/PD‑L1 treatment history and whether the patient is currently on systemic immunosuppression (a contraindication).
    Denial Risk

    Age-based review trigger — under 19 years may prompt non‑coverage

    Use in individuals under 19 years of age is a specific review trigger; pediatric use may be subject to non‑coverage if the listed pediatric criteria are not met.

    • Policy lists 'Individual is under 19 years of age' as a criterion for review.
    • Requests for pediatric use must meet the applicable diagnosis‑specific pediatric criteria to be considered medically necessary.
    Denial Risk

    Triggers for denial — prior PD‑1/PD‑L1, systemic immunosuppression, ECOG not met

    Denial is likely when the patient has prior treatment with another anti‑PD‑1 or anti‑PD‑L1 agent (where the indication excludes prior checkpoint inhibitor) or when the patient is receiving systemic immunosuppressant therapy for autoimmune/chronic conditions; failure to meet ECOG performance status requirements is also a common denial trigger.

    • Many indications explicitly require the patient 'has not received treatment with another anti‑PD‑1 or anti‑PD‑L1 agent.'
    • Active systemic immunosuppression for autoimmune disease is repeatedly listed as exclusion/contraindication.
    • ECOG performance status outside the required range (not 0–2) can render the request not medically necessary.
    Denial Risk

    Disallowed combination — do not request with IV ipilimumab (Yervoy)

    Opdivo Qvantig used in combination with intravenous ipilimumab (Yervoy) is not approved; requests for that combination or for indications that do not meet the policy criteria may be denied.

    • Package insert and policy state Opdivo Qvantig is not indicated/approved in combination with ipilimumab.
    • Policy exclusion language: 'When Opdivo Qvantig is used in combination with intravenous ipilimumab (Yervoy)' is a non‑approval condition.

    Billing and diagnosis coding

    Covered HCPCSHCPCS
    J9289HCPCS code for Injection, nivolumab and hyaluronidase (Opdivo Qvantig)
    Diagnosis ICD-10-CM ranges referencedICD-10
    C00.0-C06.9Malignant neoplasm of lip, tongue, oral cavity
    C09.0-C13.9Malignant neoplasm of tonsil, oropharynx, nasopharynx, pyriform sinus, hypopharynx
    C14.0-C14.8Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx
    C15.3-C16.9Malignant neoplasm of esophagus, stomach
    C17.0-C20Malignant neoplasm of small intestine, colon, rectosigmoid junction, rectum
    C21.0-C21.8Malignant neoplasm of anus and anal canal
    C22.0Liver cell carcinoma
    C22.8Malignant neoplasm of liver, primary, unspecified as to type
    C22.9Malignant neoplasm of liver, not specified as primary or secondary
    C30.0Malignant neoplasm of nasal cavity
    1–10 of 55
    1/6
    inv-19: Tumor Mutational Burden — TMB ≥10 mut/Mb (TMB-H); ultra-hypermutated e.g., TMB >50 mut/Mb
    TMB ≥10 mut/Mb (TMB-H)Tumor mutational burden defined as high when ≥10 mutations per megabase; used across multiple indications as a biomarker for eligibility
    Ultra-hypermutated exampleThe policy distinguishes ultra-hypermutated tumors (e.g., TMB >50 mut/Mb) for POLE/POLD1-related indications
    Clinical documentationTMB numeric result is expected in prior authorization when TMB is cited as an eligibility criterion
    inv-20: ECOG Performance Status — ECOG 0-2 (or Karnofsky 60-100 where specified)
    ECOG Performance Status scaleECOG ranges from 0 (fully active) to 5 (dead); commonly required for coverage decisions
    Coverage requirementMost indications require current ECOG 0-2 (or Karnofsky 60-100 where specified) to meet criteria
    DocumentationPrior authorization should include recorded ECOG score in the clinical record when ECOG is cited
    inv-21: Tumor mutational burden noted for sarcoma criterion (≥10 mut/Mb)
    Sarcoma TMB thresholdSoft tissue sarcoma eligibility includes unresectable/metastatic TMB-high tumors defined as TMB ≥10 mut/Mb
    Alternative histologiesCoverage also available for specific histologic subtypes (e.g., myxofibrosarcoma, UPS, dedifferentiated liposarcoma)
    Authorization noteTMB result should be provided when used as the eligibility basis
    inv-22: Ultra-hypermutated phenotype — TMB >50 mut/Mb referenced for POLE/POLD1
    Ultra-hypermutated phenotype definedUltra-hypermutated phenotype example provided as TMB >50 mut/Mb when linked to POLE/POLD1 mutations
    Indication examplesApplied to appendiceal and colorectal cancer pathways in the policy when POLE/POLD1 are present
    Testing expectationMutation testing and TMB numeric result should be included in prior authorization when used to establish eligibility
    inv-23: PD-L1 CPS — CPS ≥ 1% for certain indications
    PD-L1 CPS ≥1%PD-L1 combined positive score (CPS) ≥1% is required for specified vaginal/cervical/local-regional recurrence indications
    PD-L1 tumor proportion ≥1%For metastatic NSCLC with brain metastases, PD-L1 tumor proportion score ≥1% is required (NCCN 2A)
    Record requirementPD-L1 testing results must be supplied in prior authorization when PD-L1 is an eligibility criterion

    Definitions and clinical terms

    inv-37: ECOG Performance Status — scale description and relevance
    ECOG scale descriptionECOG performance status assesses disease impact and daily living ability; values 0-5 with definitions (0 = fully active; 5 = dead)
    Use in policyECOG used to determine suitability for nivolumab across indications; many require ECOG 0-2
    DocumentationECOG score should be documented in the medical record for prior authorization
    inv-38: Line of Therapy — definitions for sequencing
    First-, second-, third-line definitionsFirst-line = initial primary treatment; Second-line = treatment after progression on first-line; Third-line = treatment after progression on first- and second-line therapies
    Policy applicationPolicy lists first-line (e.g., ESCC with chemotherapy), neoadjuvant, adjuvant, and subsequent-line uses per tumor-specific indications
    Prior therapy documentationPrior authorization must include therapy history to establish correct line of therapy when required
    inv-39: Immune checkpoint inhibitor / PD-1 / PD-L1 — class definition and examples
    Immune checkpoint inhibitor classAgents that block PD-1 or PD-L1 (e.g., nivolumab, pembrolizumab, atezolizumab) to enhance T-cell–mediated tumor killing
    Examples in policyNivolumab (Opdivo Qvantig) is the PD-1 inhibitor addressed; other PD-1/PD-L1 agents are referenced as prior-therapy exclusions
    Coverage implicationPrior exposure to another anti-PD-1/PD-L1 agent commonly disqualifies an indication unless the policy specifies otherwise
    inv-40: TMB-H / ultra-hypermutated — thresholds such as ≥10 mut/Mb and >50 mut/Mb
    TMB-H and ultra-hypermutated thresholdsTMB-high defined as ≥10 mut/Mb; ultra-hypermutated phenotype example threshold >50 mut/Mb
    Use across indicationsTMB thresholds are used variably (e.g., ≥10 mut/Mb for TMB-H sarcoma eligibility; >50 mut/Mb for POLE/POLD1 ultra-hypermutated tumors)
    DocumentationNumeric TMB result should be included in prior authorization when TMB is cited as eligibility
    inv-41: ECOG performance status 0-2 — functional status requirement repeated across criteria
    ECOG 0-2 requirement repeatedCurrent ECOG performance status of 0-2 is repeatedly required across many indications in the policy
    Karnofsky alternativeWhere specified, Karnofsky 60-100 may be accepted as equivalent to ECOG 0-2
    DocumentationECOG or Karnofsky score must be recorded in prior authorization documentation when required
    inv-42: Actionable molecular markers — list for recommended testing prior to therapy
    Actionable molecular markers listRecommended pre-treatment testing: EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET, RET, ERBB2 (HER2), and NRG1
    Testing guidanceNCCN recommends testing these markers prior to initiating therapy; repeat biopsy or plasma testing if tissue insufficient
    Clinical purposeResults guide therapy selection and inform whether PD-1 therapy is appropriate in presence of driver oncogenes

    Background and drug description

    Background: Opdivo Qvantig is a subcutaneous formulation combining nivolumab with hyaluronidase. It is provided as an alternative formulation intended to substitute for intravenous nivolumab in indications supported by the FDA or by NCCN recommendations where substitution is appropriate.

    Policy revision history

    2025-05-16criteria_updateLatest

    Select review aligned Opdivo updates to Opdivo Qvantig criteria; added criteria for CLL/SLL; clarified colorectal cancer FDA indications; clarified relapsed/refractory Hodgkin lymphoma and combination use with AVD; added cetuximab use in SCCHN and removed duplicative criteria; coding updated (removed HCPCS NOC codes C9399, J9999 and added HCPCS J9289 effective 2025-07-01 and multiple ICD-10-CM ranges).

    2025-02-21initial_policy_release

    Select review: initial review of Opdivo Qvantig (nivolumab-hyaluronidase) including criteria for monotherapy and chemotherapy combination use from NCCN 1 and 2A recommendations; coding reviewed and HCPCS NOC C9399 and J9999 and diagnosis pend added for Opdivo Qvantig.